FII backs Healthware Group

Following the deal, FII will deploy €6m in a capital increase, co-investing alongside the current shareholders, who will inject an additional €4m to boost the growth of the group.

FII senior partner Mauro Pretolani will join the board of Healthware to support the management in this new phase of expansion.

The GP deployed capital from its FII Tech Growth Fund, which was launched with a €150m target and held a €50m first close in September 2017. The vehicle buys majority and minority stakes in small and medium-sized Italian companies with a turnover of €5-70m by deploying equity tickets between €5-20m. This is the fourth investment made by FII Tech Growth, which brings the total amount of capital deployed by the fund to around €30m.

Healthware intends to use the capital injected to invest in R&D and accelerate the development of the business with a special focus on digital health, digital therapeutics, health insurance, artificial intelligence and smart data applications in the healthcare sector.

Company
Healthware was established in 2006 and is headquartered in Salerno, with offices in Milan, London and New York. The company provides companies and startups in the healthcare sector with digital marketing, media strategy and communication consultancy services. 

The company's portfolio of clients includes Alnylam, AstraZeneca, Bayer, Boston Scientific, Cardif, Menarini, Merck, Novartis, Orion, Pfizer, Polifarma, Roche and Sanofi. Healthware generated revenues of around €5.5m in 2017.

People
Fondo Italiano d'Investimento – Carlo Mammola (CEO); Mauro Pretolani (senior partner).
Healthware Group – Roberto Ascione (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• Southern Europe
• Media
• Venture
• Italy
• Fondo Italiano di Investimento